breast cancer - adjuvant | breast cancer - HR positive | ||
breast cancer - adjuvant | la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | |
palbociclib plus endocrine therapy | PENELOPE-B | KCSG-BR15-10 | PENELOPE-B |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -